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Langerhans cells are MHC class II (Ia) positive antigen-
presenting cells that play a crucial role in the induction
of contact hypersensitivity (CHS). The topical application
of a hapten modifies the cell surface moieties of
Langerhans cells, and activates Langerhans cells to
increase their size and Ia intensity. The haptenated and
activated Langerhans cells emigrate from the epidermis
and thus the in situ density of Langerhans cells usually
decreases during 24–48 h after the hapten application in
CHS. To determine whether the early activation pattern
of Langerhans cells is different between the afferent phase
and the efferent phase of CHS, we compared the density
Contact hypersensitivity (CHS) represents a highlyspecific, long-lived, and reproducible delayed-typehypersensitivity that is a very useful experimental modelor prototype to analyse T cell-mediated cutaneousinflammation (Ptak et al, 1980; Katz, 1993). Topical
application of an antigenic hapten to skin can sensitize the individual
(afferent or inductive phase), and the epicutaneous readministration of
the identical hapten induces hapten-specific dermatitis of delayed-onset
at 24–48 h (efferent or elicitation phase) (Botham et al, 1987; Kalish,
1991; Katz, 1993).
In the afferent phase of CHS, there is ample evidence that
Langerhans cells play a pivotal role in compelling the sensitization
(Toews et al, 1980; Kripke and McClendon, 1986; Kripke et al,
1990). Langerhans cells are Ia-positive epidermal dendritic cells that
act as potent antigen-presenting or accessory cells for primary and
secondary T cell-dependent immune responses (Silberberg et al,
1974; Stingl et al, 1978; Toews et al, 1980; Inaba et al, 1986;
Kalish, 1991; Katz, 1993; Steinman et al, 1995). The Langerhans
cell-containing epidermal cells can sensitize mice to haptens (Tamaki
et al, 1981; Furue and Tamaki, 1985; Sullivan et al, 1985), and
Langerhans cells can directly induce antigen-specific T cells (Stingl
et al, 1978; Hauser, 1990). Resident epidermal Langerhans cells are
immature antigen-presenting cells (APC), but mature into potent
APC after capturing antigen. The topical application of a hapten
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and morphologic changes of Langerhans cells in CHS to
trinitrochlorobenzene using nonsensitized and sensitized
mice. We found that the application of a hapten induces
more significant enlargement of Langerhans cell size in
the afferent phase than in the efferent phase, whereas the
reduction of Langerhans cell density is more marked in
the efferent than in the afferent phase of CHS. Moreover,
topical immunosuppressive drugs inhibit the in situ activa-
tion of Langerhans cells. Key words: contact hypersensitivity/
cyclosporinee/FK-506/Langerhans cells. Journal of Investigative
Dermatology Symposium Proceedings 4:164–168, 1999
modifies the cell surface moieties of Langerhans cells, and activates
Langerhans cells to increase their size and Ia intensity (Aiba et al,
1984; Aiba and Katz, 1990). The enlargement of Langerhans cell
size in situ seems to be closely associated with their functional
maturation because quite similar enlargement occurs in cultured
Langerhans cells that acquire very potent immunostimulatory function
in vitro (Schuler and Steinman, 1985; Shimada et al, 1987; Witmer-
Pack et al, 1988; Kawamura and Furue, 1995). The haptenated and
activated Langerhans cells emigrate from the epidermis to the dermis
and then into the regional lymph nodes where they can sensitize
T cells (Kripke et al, 1990; Katz, 1993). The emigration of stimulated
Langerhans cells causes a decrease of in situ density of Langerhans
cells in the allergic and occasionally irritant CHS in mice and
humans (Aiba et al, 1984; Botham et al, 1987; Marks et al, 1987;
Hanau et al, 1989; Fujita et al, 1990; Willis et al, 1990). In skin
transplant experiments, Langerhans cells in epidermal sheets from
allograft, isograft, and explants dramatically increase not only in size
but also in terms of their immunostimulatory function, and their
numbers are markedly decreased (Larsen et al, 1990), indicating that
there is a close relationship between the morphologic alteration and
the emigration of Langerhans cells.
Although the in situ activation pattern (enlargement and decreased
density) of Langerhans cells is well documented in the afferent phase
and efferent phase of CHS, little is known about whether the dynamic
activation pattern of Langerhans cells is different between the afferent
phase and the efferent phase of CHS. We have compared the density
and morphologic changes of Langerhans cells in situ in the afferent
and efferent phases of CHS to trinitrochlorobenzene (TNCB) using
nonsensitized and sensitized mice. We demonstrate that the activation
pattern (decrease of density or increase of size) of Langerhans cells is
differentially regulated in the afferent phase and efferent phase of CHS,
and that topical immunosuppressive drugs inhibit the in situ activation
of Langerhans cells.
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Figure 1. Time course of ear swelling after 1% TNCB painting in the
unsensitized (afferent phase) and sensitized (efferent phase) mice.
Marked ear swelling was observed in the sensitized mice when compared with
the control olive oil application. Slight ear swelling was evident in the
unsensitized mice. n, Olive oil only (n 5 8); s, TNCB painting (unsensitized
group) (n 5 17); d, TNCB painting (sensitized group) (n 5 22). Data show
mean 6 SD. **p , 0.01.
MATERIALS AND METHODS
Animals Female C3H/HeN mice, 8–12 wk old, were obtained from Shizuoka
Agricultural Cooperative Association for Laboratory Animals (Hamamatsu,
Japan).
Reagents 2,4,6-Trinitrochlorobenzene (TNCB) was obtained from ICN
Pharmaceuticals (Plainview, NY). Anti-I-Ak (clone,11–5.2: mouse IgG2b) and
control mouse IgG2b antibodies were purchased from Pharmingen (San Diego,
CA). FITC-conjugated goat antimouse IgG was obtained from Cappel (Durham,
NL). Dexamethasone (DEX) was purchased from Sigma (St Louis, MO).
Cyclosporinee A (CS) was obtained from Sandoz (Tokyo, Japan). FK-506 was
obtained from Fujisawa (Osaka, Japan).
Sensitization and elicitation of CHS C3H mice were sensitized by
epicutaneous application of 100 µl of 7% TNCB in a 4:1 acetone:olive oil
mixture on the shaved abdomen as previously described (Furue and Tamaki,
1985). Six days later, 20 µl of 1% TNCB in olive oil was topically applied on
the ears of sensitized and nonsensitized mice. The olive oil application served
as a solvent control. Ear thickness was quantitated with a micrometer (Mitsutoyo,
Tokyo, Japan) at 2, 24, 48, 72, and 144 h after challenge, and compared with
the thickness of the same ear assessed prior to challenge. After thickness
measurement, the epidermal sheets were prepared from the ears at the same
time point and immunolabeled with anti-I-Ak antibody. From five to 15 mice
were used in each group. Experiments were performed at least three times.
We chose 20 µl of 1% TNCB in olive oil as the elicitation dose in order to
directly compare the afferent and efferent phases of CHS, because a suitable
minimum concentration of TNCB to actively induce both sensitization and
elicitation of CHS was 1% in C3H mice (data not shown), and the olive oil
diluent had no effect on the CHS response in vivo. Thus, using this experimental
protocol, we could simultaneously examine the afferent phase (using nonsensit-
ized mice) and the efferent phase (sensitized mice) of CHS for the same amounts
of the hapten.
Separation and immunostaining of epidermal sheet The ears were first
mechanically divided into dorsal and ventral sides of cutaneous sheets. The
epidermis was then separated from the dermis after incubation with 3.8%
ammonium thiocyanate (Sigma). After the fixation with acetone at –20°C for
20 min, the epidermal sheets were incubated with anti-I-Ak or control mouse
IgG2b antibodies overnight at 37°C, washed with phosphate-buffered saline,
and further incubated with FITC-conjugated goat antimouse IgG for 2 h at
Figure 2. Time course of Langerhans cell density after 1% TNCB
painting in the unsensitized and sensitized mice. A significant decrease of
Langerhans cell density was detected at 24–72 h in the sensitized mice. In the
unsensitized mice the decrease of Langerhans cell density was very weak and
was not significant. n, Olive oil only (n 5 20); s, TNCB painting (unsensitized
group) (n 5 16); d, TNCB painting (sensitized group) (n 5 16). Data show
mean 6 SD. *p , 0.05; **p , 0.01.
37°C. The stained sheets were observed by Zeiss immunofluorescence micro-
scopy. Control isotype matched mouse IgG2b always yielded negative results.
Density and relative size of Ia1 Langerhans cell in the epidermal
sheets The number of Ia1 Langerhans cells was enumerated by using a
rectangular ocular grid at a magnification of 4003. At least 10 areas of each
epidermal sheet were randomly chosen and the mean number of stained cells
per mm2 was determined in each experimental group. The density of Langerhans
cells was expressed as a relative percentage compared with the Langerhans cell
density of normal control mice standardized as 100%. The immunolabelled
Langerhans cells were then photographed at the magnification of 4003. The
images of Ia1 Langerhans cells were computerized by photoscanning. The mean
size of Langerhans cells in untreated normal mice was arbitrarily expressed as
100, and the relative size of Langerhans cells was calculated in each experimental
group using the computer program ‘‘NIH Image’’.
Effects of topical immunosuppressive drugs The immunosuppressive
activity of DEX, CS, or FK-506 had been confirmed as described previously
(Furue and Ishibashi, 1991; Furue et al, 1994). DEX, CS, and FK-506 were
dissolved in 2:1 dimethlsulfoxide:ethanol at a concentration of 1% (wt/vol).
The sensitized or nonsensitized mice were challenged as described above;
however, 1 h prior to 1% TNCB application 30 µl of 1% DEX, 1% CS,
1% FK-506, or solvent control was applied on the ear, and ear thickness
measurement and immunolabeling were performed at 24 h and 48 h after
the TNCB painting. The increase of relative Langerhans cell size and the
decrease of relative Langerhans cell density were assessed in each group.
Mean percentage inhibition of increased Langerhans cell size was calculated
by the following formula:
LC size in solvent- – LC size in drug-
treated group treated group
Mean percentage inhibition of 5 3 100(%)
increased LC size LC size in solvent- – 100
treated group
Mean percentage restoration of decreased Langerhans cell density was calculated
by the following formula:
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Figure 3. Time course of relative size of Langerhans cell after 1%
TNCB painting in the unsensitized and sensitized mice. TNCB
application induced a rapid and significant increase of the relative size of
Langerhans cell at 24 h in the unsensitized mice. The enlargement of Langerhans
cell size then rapidly normalized or even became smaller at 48 h. In the efferent
phase the enlargement of Langerhans cell size was significantly smaller, but it
lasted longer than that in the afferent phase. The enlargement of Langerhans
cell was detected at 24 h even after the application of olive oil only. n, Olive
oil only (n 5 55); s, TNCB painting (unsensitized group) (n 5 28); d,
TNCB painting (sensitized group) (n 5 30). Data show mean 6 SD. **p , 0.01.
LC density in solvent- – LC density in
treated group drug-treated group
Mean percentage inhibition 5 3 100(%)
of increased LC density LC density in solvent- – 100
treated group
Statistical analysis Student’s t test was used to analyse significance and a
p value of less than 0.05 was considered significant.
RESULTS AND DISCUSSION
Morphologic and numerical alteration of Langerhans cells are
differentially regulated in the afferent and efferent phase of
CHS We first examined the ear thickness increments after 1% TNCB
painting in the unsensitized (afferent phase) and sensitized (efferent
phase) mice. In sensitized mice, marked ear swelling was observed
24 h after the TNCB application at a peak of 48 h (Fig 1). In
unsensitized mice the application of 1% TNCB induced slight but
significant swelling at 24 h after painting when compared with control
olive oil-painted mice (Fig 1). In accordance with the ear swelling,
the epidermal density of Ia1 Langerhans cells was significantly reduced
at 24–72 h in the sensitized mice (Fig 2). The number of Langerhans
cells also tended to decrease in the unsensitized mice; however, the
reduction was transient and was not statistically significant (Fig 2).
With regard to the morphologic alteration of Langerhans cells, the
TNCB application resulted in a rapid and significant increase of the
relative size of Langerhans cells at 24 h in the unsensitized mice (Fig 3).
The enlargement of Langerhans cell size then rapidly normalized or
even became smaller at 48 h. In contrast, TNCB application also
Figure 4. Effects of topical FK-506, CS, and DEX on the enlargement
of Langerhans cell size in the unsensized mice. The solvent control did
not affect the activation pattern of Langerhans cells, and the relative size of
Langerhans cells increased in the unsensitized mice. FK-506, CS, and DEX
each clearly inhibited the enlargement of Langerhans cell size induced by the
TNCB application. Data show mean 6 SD. *p , 0.05; #p 5 0.0702.
increased the relative size of Langerhans cells at 24 h in the sensitized
mice, but the increase was much less than that of the unsensitized
mice (Fig 3). The increase of relative size of Langerhans cells at 24 h
in the sensitized mice was not statistically significant compared with
the control olive oil application group, because the enlargement of
Langerhans cells was detected at 24 h even after the application of
olive oil only (Fig 3). In the sensitized mice, however, the enlargement
of Langerhans cells lasted longer up to 72 h, and thus significant
increments of Langerhans cell size were recognized at 48 h and 72 h
when compared with olive oil application (Fig 3).
The critical difference between the afferent and efferent phases
of CHS was the absence or presence of dermal infitrates, which
were mainly composed of lymphoid cells, neutrophils, and eosinophils.
In the afferent phase TNCB application induced rapid and remarkable
enlargement of Langerhans cell size but not marked reduction of
Langerhans cell density. In the efferent phase the enlargement of
Langerhans cell size was significantly smaller, but it lasted longer
than that in the afferent phase. In addition, there was a marked
reduction of Langerhans cell density in the efferent phase. The
difference of activation pattern may be due to the direct effects of
infiltrated leukocytes on the Langerhans cells in the efferent phase.
Alternatively, in the efferent phase, the fully activated Langerhans
cells may smoothly and rapidly emigrate from the epidermis as early
as 24 h, and it is possible that residual Langerhans cells are an
incompletely activated or incompletely enlarged population at 24 h
after the TNCB application.
Inhibition of Langerhans cell activation by topical application
of immunosuppressive drugs Using this assay system, we next
examined the effects of FK-506, CS, and DEX on the activation
patterns of Langerhans cells in the afferent and efferent phases of
CHS. The immunosuppressive activity of these agents was very
potent because topical application of either 1% FK-506, 1% CS, or
1% DEX prior to the TNCB challenge in the sensitized mice
almost completely inhibited the ear swelling compared with solvent
control treatment (data not shown; Furue and Katz, 1989; Furue
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Table I. Effects of topical FK-506, CS, and DEX on the
Langerhans cell activation in the unsensitized (afferent phase)
and sensitized (efferent phase) mice
Mean percentage inhibition Mean percentage
of increased Langerhans cell restoration of decreased
size Langerhans cell density
24 h 48 h 24 h 48 h
Unsensitized mice (afferent phase)
FK-506 54.9% –0.1% 76.6% 100%
CS 71.2% 40.6% 69.0% 68.6%
DEX 63.5% 125.6% –0.1% –221.9%
Sensitized mice (efferent phase)
FK-506 37.9% 96.8% ND 95.3%
CS 46.8% 98.1% ND 52.2%
DEX 7.4% 77.1% ND –23.3%
et al, 1994). We assayed the effects of drugs at 24 h and 48 h after
the TNCB application. The solvent control did not affect the
activation pattern of Langerhans cells induced by the TNCB
painting, and the relative size of Langerhans cells increased in
association with reduction of density in both the unsensitized (Fig 4)
and the sensitized (data not shown) mice. Very interestingly, all the
drugs clearly inhibited the enlargement of Langerhans cell size
induced by the TNCB application in both the unsensitized and the
sensitized mice (Fig 4, Table I). In keeping with the results of
time course experiments of Langerhans cell size (Fig 3), the
inhibitory effects on Langerhans cell size by drugs were stronger at
24 h than at 48 h in the unsensitized mice (Table I). In the
sensitized mice the inhibitory effects were more clearly recognized
at 48 h than at 24 h (Table I). With regard to the decreased
Langerhans cell density, FK-506 and CS were capable of restoring
the reduction of Langerhans cell density; however, DEX not only
could not restore the decreased Langerhans cell density, but further
induced its reduction (Table I).
FK-506, CS, and DEX are potent immunosuppressive drugs that
are very useful therapeutic modalities in the dermatologic field. CS
has been shown to directly downregulate the accessory and antigen-
presenting cell function of Langerhans cells without affecting the
viability (Furue and Katz, 1988a, b). DEX also directly decreases the
number of Langerhans cells in vivo and markedly causes the viability
of Langerhans cells to deteriorate in vitro (Furue and Katz, 1989). The
cytotoxic (perhaps apoptosis-inducing) effects on Langerhans cells by
DEX may explain the continuous reduction of Langerhans cell density
after topical application (Table I). As all the drugs inhibited the
enlargement of Langerhans cell size induced by TNCB stimulation not
only in the afferent phase but also in the efferent phase, the present
data suggest that immunosuppressive drugs are likely to directly affect
the activation of Langerhans cells, and that the inhibitory effects on
Langerhans cell activation may partly participate in the profound
immunosuppressive activity of the agents.
Previous studies have disclosed that the survival and functional
maturation of Langerhans cells are profoundly supported by kera-
tinocyte-derived cytokines such as granulocyte-macrophage colony-
stimulating factor (GM-CSF), interleukin (IL)-1, and tumor necrosis
factor-α (TNF-α). GM-CSF enhances the survival and APC function
of Langerhans cells (Witmer-Pack et al, 1987). IL-1 further augments
the GM-CSF-induced functional maturation of Langerhans cells
(Heufler et al, 1988). In contrast, TNF-α is active in maintaining the
survival of Langerhans cell as potently as GM-CSF without increasing
their APC function (Koch et al, 1990). Therefore it is possible that the
immunosuppressive drugs may inhibit the release of keratinocyte-
derived cytokines, which in turn suppress the early Langerhans cell
activation.
In conclusion, these results indicate that the activation pattern of
Langerhans cells is influenced by whether the host has been previously
sensitized or not. Furthermore, the Langerhans cell activation is clearly
downregulated by the immunosuppressive drugs, suggesting that the
measurement of Langerhans cell activation may be one of the useful
screening methods to evaluate the immnosuppuressive activity of newly
developed therapeutic compounds.
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